Skip to main content

Home Activities Product Pipeline
Print Bookmark

Product Pipeline

The company is currently developing a range of pharmaceutical product projects that are mostly based on its Multi Matrix MMX® technology. This technology allows the delivery of active pharmaceutical ingredients mainly into the lumen of the colon through tablet erosion in a delayed and controlled manner. This has the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.

The company's proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases, with the group's lead product Lialda® launched in the US and EU, and with the nutraceutical Zacol NMX® launched for the local market in Italy and in selected Eastern European countries. In addition, two products are in Phase III, four in Phase II and one in phase Phase I. The group has also 3 products in preclinical phase.

Leveraging on its MMX® technology Cosmo has developed the following compound pharmaceutical products against Inflammatory Bowel Disease as well as nutraceuticals:

Graph displaying compound pharmaceutical products against Inflammatory Bowel Disease as well as nutraceuticals developed by Cosmo Link to Rifamycin pageLink to CB-03-01 pageLink to Heparin pageLink to Budesonide pageLink to Zacol pageLink to Lialda and Mesavant pageLink to CB-17-01 pageLink to CB-01-16 page